Paromomycin in the treatment of leishmaniasis

Bibliography

• Zijlstra EE, Musa AM, Khalil EA, et al. Post Kala-azar dermal leishmaniasis. Lancet Infect Dis 2003;3:87-98
   PubMed Web of Science ®Google Scholar
• Ramesh V, Mukherjee A. Post Kala-azar dermal leishmaniasis. Int J Dermatol 1995;34:85-91
   PubMed Web of Science ®Google Scholar
• WHO. Leismaniasis – burden of disease. Available from: www.whoint/leishmaniasis/burden
   Google Scholar
• WHO. Control of leishmaniasis, Report by the secretariat. EB 118/4 11th May 2006
   Google Scholar
• Desjeux P. The increase in risk factors for leishmaniasis worldwide. Trans R Soc Trop Med Hyg 2001;95:239-43
   PubMed Web of Science ®Google Scholar
• WHO. The Leishmaniasis and Leishmania/HIV co-infection Fact Sheet 116, Geneva. World Health Organization; 2000
   Google Scholar
• Minutes of the Meeting of the Expert Committee for the Treatment of Kala-azar in India. 2000. Ministry of Health, Government of India
   Google Scholar
• Cascio A, Colomba C. Childhood Mediterranean visceral leishmaniasis. Infez Med 2003;11:5-10
   PubMedGoogle Scholar
• Russo R, Nigro LC, Minniti S, et al. Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996;32:133-7
   PubMed Web of Science ®Google Scholar
• Montana M, Chochoi N, Mouges P, et al. Liposomal amphotericin B in secondary prophylaxis of visceral leishmaniasis in HIV infected patients: report of five clinical cases. Pathol Biol 2004;52:66-75
   PubMed Web of Science ®Google Scholar
• Control of the Leishmaniasis. Report of a WHO Expert Committee. World Health Organ. Tech Rep Ser 1990;793:1-158
   PubMedGoogle Scholar
• Thakur CP, Kumar M, Kumar P, et al. Rationalization of regimens of treatment of Kala-azar with sodium stibogluconate in India: a randomized study. BMJ 1988;296:1557-61
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh VP, Sharma S, et al. Response to interferon-gamma plus pentavalent antimony in Indian visceral Leishmaniasis. J Infect Dis 1997;176:1117-9
   PubMed Web of Science ®Google Scholar
• Jha SN, Singh NK, Jha TK. Changing response to diamidine compounds in cases of Kala-azar unresponsive to antimonials. J Assoc Phys India 1991;39:314-6
   PubMedGoogle Scholar
• Mishra M, Singh MP, Choudhury D, et al. Amphotericin B for second line treatment of Indian Kala-azar. Lancet 1991;337:926
   PubMedGoogle Scholar
• Jha TK, Sundar S, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46
   PubMed Web of Science ®Google Scholar
• Jha T, Sundar S, Thakur CP, et al. A phase II dose-rising study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg 2005;73(6):1005-11
   PubMed Web of Science ®Google Scholar
• Wassuna M, Felton J, Sabin A, Horton J. A phase II dose-rising study of sitamaquin for the treatment of visceral leishmaniasis in Kenya. Am J Trop Med Hyg 2005;73(5):871-6
   PubMed Web of Science ®Google Scholar
• Tracy JW, Wbester LT Jr. Drugs used in the chemotherapy of protozoal infections (continued). In: Hardman JG, Limbird LE, editors. The pharmacological basis of therapeutics. Goodman and Gilman's 10th edition McGraw Hill, New York, 2001. Chapter 41:1097-120
   Google Scholar
• Moore TA. Agents used to treat infections due to parasites and pneumocystis. In: Kasper DL, Fauci AS, Longo DL, et al. editors. Harrison's principles of internal medicine, 16th edition. Volume I, Chapter 93:1202-14
   Google Scholar
• Novarini A, Montanari H, Bruschi G, et al. The kinetics of aminosidine in renal patients with different degrees of renal failure. Clin Nephrol 1975;4(1):23-4
   PubMedGoogle Scholar
• Kanyok TP, Killian AD, Rodvold AK, Daniziger LH. Pharmacokientics of intramuscularly administered Paromomycin in Healthy subjects. Antimicrob Agents Chemother 1997;41(5):982-6
   PubMed Web of Science ®Google Scholar
• Kshirsagar S, Mordenti J, Blaschke T. Population pharmacokinetics of aminosidine sulfate in Indian visceral leishmaniasis Patients. Available from: http://mednet3.who.int/EMI/expcom/expcom15/applications/newmed/paromomycin/PharmacokineticsCAAC2006.pdf
   Google Scholar
• Neal RA. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann Trop Med Parasitol 1968;62:54-62
   PubMed Web of Science ®Google Scholar
• Chunge CN, Owate J, Pamba HO, Donno L. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990;84:221-5
   PubMed Web of Science ®Google Scholar
• Seaman J, Pryce D, Sondorp HE, et al. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J Infect Dis 1993;168:175-720
   Google Scholar
• Thakur CP, Olliaro P, Gothoskar S, et al. Treatment of visceral leishmaniasis (Kala-azar) with aminosidine (paromomycin) – antimonial combinations: a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 1992;86(6):615-6
   PubMed Web of Science ®Google Scholar
• Melaku Y, Collin SM, Keus K, et al. Treatment of Kala-azar in Southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30 day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007;77(1):89-94
   PubMed Web of Science ®Google Scholar
• Jha TK, Olliaro P, Thakur CPN, et al. Randomized controlled trial of aminosidine (paromomycin)vs sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kanyok TP, Pandey AK, et al. A prospective randomized comparative open label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for visceral leishmaniasis. Trans R Soc Trop Med Hyg 2000;94(4):429-31
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007;356:2571-81
   PubMed Web of Science ®Google Scholar
• el-On J, Halevy S, Grunwald MH, Weinrauch L. Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major. A double blind control study. J Am Acad Dermatol 1992;27:227-31
   PubMed Web of Science ®Google Scholar
• Asilian A, Jalayer T, Whitworth JA, et al. A randomized, placebo-controlled trial of a two-week regimen of Paromomycin (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995;53:648-51
   PubMed Web of Science ®Google Scholar
• Ben Salah A, Zakraoui H, Zaatour A, et al. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995;53:162-66
   PubMed Web of Science ®Google Scholar
• Asilian A, Jalayer T, Nilforoosh Zadeh M, et al. Treatment of cutaneous leishmaniasis with Paromomycin (paromomycin) ointment: double blind randomized trial in the Islamic Republic of Iran. Bull World Health Organ 2003;81(5)
   PubMedGoogle Scholar
• Arana BA, Mendoza CE, Rizzo NR, et al. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 2001;65:466-70
   PubMed Web of Science ®Google Scholar
• Krause G, Kroeger A. Topical treatment of American cutaneous leishmaniasis with paromomycin and methylbenzethonium chloride, a clinical study under field conditions in Ecuador. Trans R Soc Trop Med Hyg 1994;88:92-4
   PubMed Web of Science ®Google Scholar
• Soto JM, Toledo JT, Gutierrez P, et al. Treatment of cutaneous leishmaniasis with a topical antileishmanial drug(WR279396): phase 2 pilot study. Am J Trop Med Hyg 2002;66:147-51
   PubMed Web of Science ®Google Scholar
• Sundar S, Rai M. Treatment of visceral leishmaniasis. Expert Opin Pharmacother 2005;6(16):2821-9
   PubMed Web of Science ®Google Scholar